Aridis Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Aridis Pharmaceuticals, Inc.

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-…

Biotechnology
US, Los Gatos [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Aridis Pharmaceuticals, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of ARDS's Analysis
CIK: 1614067 CUSIP: 040334104 ISIN: US0403341045 LEI: - UEI: -
Secondary Listings
ARDS has no secondary listings inside our databases.